Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can eczema patients safely take less dupilumab? new trial aims to find out

NCT ID NCT05642208

Ongoing Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether people with atopic dermatitis (eczema) that has been well-controlled for at least six months can safely take dupilumab less often. About 256 teens and adults will either stick with their usual every-two-week injection or gradually space out doses. The goal is to see if the step-down approach keeps the disease under control just as well over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dupilumab
What this could lead to
If successful, this could show that patients with well-controlled atopic dermatitis can safely take dupilumab less often while still keeping symptoms under control.
What could go wrong
This is a Phase 4 trial, so dupilumab is already approved. The main question is whether reducing the dose will cause a flare-up in some patients. Results may not apply to those with more severe or uncontrolled disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ECZEMA, ATOPIC

Contacts and locations

Locations

  • Amiens University hospital

    Amiens, France

  • CH de Le Mans

    Le Mans, France

  • CH de Niort

    Niort, France

  • CH de Saint Nazaire

    Saint-Nazaire, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHRU de Brest

    Brest, France

  • CHRU de Lille

    Lille, France

  • CHRU de Tours

    Tours, France

  • CHU d'Angers

    Angers, France

  • CHU de Besançon

    Besançon, France

  • CHU de Bordeaux Adulte

    Bordeaux, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Dijon

    Dijon, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de La Réunion

    Saint-Pierre, La Réunion, Reunion

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nantes

    Nantes, France

  • CHU de Poitiers

    Poitiers, France

  • CHU de Reims

    Reims, France

  • CHU de Rennes

    Rennes, France

  • CHU de Rouen

    Rouen, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, France

  • GH La Rochelle - Ré-Aunis

    La Rochelle, France

  • Groupement des Hôpitaux de l'institut Catholique de Lille

    Lille, France

  • HIA Sainte Anne

    Toulon, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Necker-Enfants malades

    Paris, France

  • Hôpital Saint Louis

    Paris, France

  • Hôpital Tenon

    Paris, France

  • Hôpital Victor Dupouy

    Argenteuil, France

  • Hôpital de la Timone

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.